ANI Pharmaceuticals

ANIP · NASDAQ🇺🇸

Overview

Earnings Dividends Seasonality Metrics

Reported earnings about 1 month ago

Cortrophin Gel Growth

87.6%

Generics Revenue Growth

28.2%

Gross Profit

$147M

Previous year: $87.7M

Previous year: $1.28B

+12.2%

Loading...

ANI Pharmaceuticals

Unlock previous datapoints

Upgrade

ANI Pharmaceuticals

Unlock previous datapoints

Upgrade

ANI Pharmaceuticals Revenue by Segment

Revenue by Segment

Cortrophin Gel Revenue

CapyFin.com

ILUVIEN Revenue

CapyFin.com

Rare Disease Total Revenue

CapyFin.com

Brands Revenue

Unlock previous datapoints

Upgrade

CapyFin.com

Generic Products Revenue

Unlock previous datapoints

Upgrade

CapyFin.com

Royalties and Other Revenue

Unlock previous datapoints

Upgrade

CapyFin.com

Generics and Other Total Revenue

CapyFin.com

Revenue & Expenses

Visualization of income flow from segment revenue to net income

Historical Earnings Impact

Analyze how earnings announcements historically affect stock price performance

Avg. Return Before/After Earnings

Loading earnings performance data...

Loading earnings reaction data...

Key Statistics

Market Cap

$1.76B

P/E Ratio

9.95

Sector

N/A

Industry

N/A

52-Week High

$98.7

52-Week Low

$57.1

Total Revenue Growth

29.6%

Cortrophin Gel Growth

87.6%

Generics Revenue Growth

28.2%

Adjusted EBITDA Growth

30.6%

Products

Get in Touch

Resources

ANI Pharmaceuticals

ANI Pharmaceuticals

ANI Pharmaceuticals

ANI Pharmaceuticals Revenue by Segment

Revenue by Segment

Cortrophin Gel Revenue

ILUVIEN Revenue

Rare Disease Total Revenue

Brands Revenue

Generic Products Revenue

Royalties and Other Revenue

Generics and Other Total Revenue

Revenue & Expenses

Historical Earnings Impact

Avg. Return Before/After Earnings

Key Statistics